These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22335887)

  • 1. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features.
    Sekine A; Kato T; Hagiwara E; Shinohara T; Komagata T; Iwasawa T; Satoh H; Tamura K; Kasamatsu T; Hayashihara K; Saito T; Takahashi H; Ogura T
    Lung Cancer; 2012 Jul; 77(1):64-9. PubMed ID: 22335887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Miliary metastases are associated with epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based study.
    Hsu F; Nichol A; Toriumi T; De Caluwe A
    Acta Oncol; 2017 Sep; 56(9):1175-1180. PubMed ID: 28521651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer.
    Li H; Zhang X; Cao J; Su P; Lian J; Song X; Yang W; Han S; Xi Y; Wang Y
    Tumour Biol; 2015 Dec; 36(12):9251-8. PubMed ID: 26091796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
    Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
    Weber B; Winterdahl M; Memon A; Sorensen BS; Keiding S; Sorensen L; Nexo E; Meldgaard P
    J Thorac Oncol; 2011 Jul; 6(7):1287-9. PubMed ID: 21847041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.
    Chonan M; Narita N; Tominaga T
    BMC Res Notes; 2016 Jan; 9():2. PubMed ID: 26724810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan.
    Guan J; Chen M; Xiao N; Li L; Zhang Y; Li Q; Yang M; Liu L; Chen L
    Med Oncol; 2016 Jan; 33(1):1. PubMed ID: 26589606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
    Song Z; Zhang Y
    J Clin Neurosci; 2014 Apr; 21(4):591-5. PubMed ID: 24256883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.
    Daniele L; Cassoni P; Bacillo E; Cappia S; Righi L; Volante M; Tondat F; Inghirami G; Sapino A; Scagliotti GV; Papotti M; Novello S
    J Thorac Oncol; 2009 Jun; 4(6):684-8. PubMed ID: 19404216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases.
    Ge M; Zhuang Y; Zhou X; Huang R; Liang X; Zhan Q
    J Neurooncol; 2017 Nov; 135(2):413-418. PubMed ID: 28780743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
    Igawa S; Kasajima M; Ishihara M; Kimura M; Hiyoshi Y; Asakuma M; Otani S; Katono K; Sasaki J; Masuda N
    Oncology; 2014; 87(4):215-23. PubMed ID: 25034225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
    Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
    J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion.
    Laack E; Simon R; Regier M; Andritzky B; Tennstedt P; Habermann C; Verth CZ; Thöm I; Grob T; Sauter G; Bokemeyer C
    J Thorac Oncol; 2011 Jan; 6(1):199-202. PubMed ID: 21178715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
    Onitsuka T; Uramoto H; Nose N; Takenoyama M; Hanagiri T; Sugio K; Yasumoto K
    Lung Cancer; 2010 May; 68(2):198-203. PubMed ID: 19589612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.